Dupixent and Narrowband UVB for Atopic Dermatitis

Purpose

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Condition

  • Atopic Dermatitis

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female adult ≥ 18 years of age; - Diagnosis of moderate to severe atopic dermatitis as defined at baseline by: - EASI score of 16 or greater, - IGA score of 3 or greater - BSA of 10% or greater,

Exclusion Criteria

  • Subjects with previous exposure to dupilumab. - Known or suspected hypersensitivity to dupilumab or any of its excipients. - History of photosensitivity.

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Dupixent and Narrowband UVB 		Dupixent and Narrowband UVB
  • Drug: Dupixent
    dupilumab 300mg

Recruiting Locations

Eczema Treatment Center of New Jersey
East Windsor, New Jersey 08520
Contact:
Elise Nelson
609-443-4500
enelson@windsordermatology.com

More Details

Status
Recruiting
Sponsor
Psoriasis Treatment Center of Central New Jersey

Study Contact

Elise Nelson
6094434500
enelson@windsordermatology.com

Detailed Description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.